Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Investor Presentation (February 2021)
23 slides from Scisparc's investor presentation, Feb 24, 2021
Slide 1: SciSparc Corporate Presentation February 2021
SciSparc Corporate Presentation February 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation of SciSparc Ltd. (the “ Company ” ) contains “ forward - looking statements ” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “ expects, ” “ anticipates, ” “ intends, ” “ plans, ” “ believes, ” “ seek
Slide 3: Our Vision
To bridge cannabis and cannabinoids to the healthcare system to improve the health and wellbeing of patients Our Vision
Slide 4: SciSparc Company Highlights
SciSparc Company Highlights • Developing cannabinoid - based therapies • Science driven and targeted treatment solutions • New, committed experienced managment • Entourage Effect seeks to increase efficiency, lower dosage and side effects • Our intellectual property portfolio comprises three granted
Slide 5: The SciSparc Story
The SciSparc Story A specialty pharmaceutical company focused on repurposing approved cannabinoids for new indications Platform Programs SCI - 110 An innovative and proprietary drug candidate platform based on U.S. Food and Drug Administration (FDA) approved THC and the endocannabinoid Palmitoyletha
Slide 6: The Entourage Effect
T h e “ Entourag e Effect ” The "Entourage Effect", first described by Prof. Raphael Mechoulam in 1998 * Effects of the Endocannabinoid system can be explained by its overall constituents working together, synergistically, rather to any single component The Entourage technology is the basis of all t
Slide 7: SciSparc Platform: Entourage Effect
SciSparc Platform Seeking to Increase Efficiency, Lower Dosage and Fewer Side Effects “ The Entourage Effect “ SciSparc ’ s proprietary combination of CannAmide TM and any Cannabinoid creating an “ Entourage Effect ” , first discovered by Prof. Raphael Mechoulam in 1998 , which results in synergy. C
Slide 8: Harnessing the Entourage Effect Phenomenon
SciSparc Platform: Harnessing the Entourage Effect Phenomenon Seeking to Improve Efficacy and Minimize Psychological Side Effects Dose Matters Dosage regiment may compromise therapeutic benefits of cannabis and may severely impact treatment • Serious diminishing effect over time and extensive use •
Slide 9: Tourette Syndrome Disease Overview & Clinical Features
Tourette Syndrome (TS) Disease Overview & Clinical Features Disease Overview • TS is a movement and neurobehavioral disorder characterized by motor and vocal chronic tics with onset before age 18 • About half to two - thirds of the cases get much better during adolescence 1 • However, adults will ge
Slide 10: TS Phase IIa Clinical Trial
TS Phase IIa Clinical Trial SCI - 110 : Seeking to Provide Increased Efficiency, Lower Dosage and Fewer Side Effects TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co - morbidities We believe that topline results from our trial conducted
Slide 11: TS Phase IIb Clinical Trial
TS Phase IIb Clinical Trial SCI - 110 : Seeking to Provide Increased Efficiency, Lower Dosage and Fewer Side Effects • SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI - 110 in a randomized, double - blind, placebo controlled, cross - over study • The study is expected t
Slide 12: SCI-110 for Obstructive Sleep Apnea (OSA)
SCI - 110 for Obstructive Sleep Apnea (OSA) Seeking to Provide Increased Efficiency, Lower Dosage and Side Effects OSA causes breathing to repeatedly stop during sleep and is a potentially lethal sleep disorder. There are currently no FDA approved pharmaceutical therapies to treat this disorder 1 1
Slide 13: OSA Phase IIa Clinical Trial
OSA Phase IIa Clinical Trial We Believe that Topline Results from our Trial Conducted in Assuta Sleep Clinic in 2019 Show Encouraging Results: • Of the 10 patients recruited into the study, nine patients have completed the study and one has dropped out of the study due to treatment associated advers
Slide 14: SCI-110 for Alzheimer's Disease and Agitation
SCI - 110 for Alzheimer ’ s Disease and Agitation Seeking to Provide Increased Efficiency, Lower Dosage and Fewer Side Effects • Dementia is a clinical syndrome characterized by progressive decline in two or more cognitive domains, including memory, language, executive and visuospatial function, per
Slide 15: SCI-210 for Autism Spectrum Disorder (ASD)
SCI - 210 for Autism Spectrum Disorder (ASD) Autism: A Rapidly Growing Population with Array of Symptoms clinical study conducted by the company - Based on a pre 1 PEA Significantly Increases CBD Effects 1 CBD was shown to prevent fat accumulation in liver cells in a concentration dependent manner P
Slide 16: SCI-160 for Pain
SCI - 160 for Pain • An innovative and proprietary CB 2 Receptor Agonist formulation intended for the treatment of pain. This specific CB 2 receptor agonist was synthesized by Professor Raphael Mechoulam, Ph.D. • SCI - 160 , a synthetic CB 2 Receptor Agonist, which is protected under a patent grante
Slide 17: CannAmide (TheraPEA) – For pain and inflammation
CannAmide Ρ CannAmide TM (TheraPEA) – For pain and inflammation: • Active ingredient Palmitoylethanolamide – Advantages over other PEA products x CannAmide is a special formulation designed to increase PEA solubility and absorption as opposed to most if not all PEA products available as yet on the m
Slide 18: CannAmide (TheraPEA) – For pain and inflammation
CannAmide Ρ CannAmide TM (TheraPEA) – For pain and inflammation: • Active ingredient Palmitoylethanolamide – • Endocannabinoid - like compound, a lipid - messenger and an endogenous neuromodulator with a broad spectrum of pharmacological properties and can be found naturally in the body, as well as
Slide 19: Pipeline
Pipeline COMPOUND SCI – 110 THERAPEUTIC AREA PRECLINICAL Medical Cannabis route PHASE IIa PHASE IIb TOURETTE SYNDROME OBSTRUCTIVE SLEEP APNEA SCI – 110 SCI – 110 AUTISM SCI – 160 PAIN CannAmide Œ ANTI - INFLAMMATORY TO HELP RELIEVE CHRONIC PAIN (COMMERCIAL) SCI - 110 – trans - Δ ⁹ - tetrahydrocannab
Slide 20: Highlights
Highlights • We believe that we have unique technologies in the medical cannabis market • Focus on cannabinoid family products with unique and proprietary combinations, methods of administrations and formulations • Pursuing new high potential R&D and clinical programs • Advanced clinical programs •
Slide 21: SciSparc's Management
SciSparc ’ s Management Amitai Weiss, CEO Mr. Weiss currently serves as chairman of the board of directors of P.L.T Financial Services Ltd., as chairman of the board o f directors of Matomy Media Group Ltd. and as an external director of Cofix Group Ltd. In 2016 , Mr. Weiss founded Amitay Weiss Mana
Slide 22: SciSparc's Board of Directors
SciSparc ’ s Board of Directors Lior Amit , Director Mr. Amit serves as a consultant to both private and public companies as well as individuals. Mr. Amit serves as director of ScoutCam Inc., Matomy Ltd., Nirplex Ltd., Ronimar Ltd., Endemol Israel Ltd. and B.S.S.CH. - The Israeli Credit Insurance Co
Slide 23: SciSparc Scientific Advisory Board
CNS Endocannabinoids and PEA Pain Dr. Michael Bloch Prof. James Leckman Prof. Raphael Mechoulam Prof. Avi Weizman Prof. Kirsten Muller - Vahl Prof. Michael Davidson Prof. Elon Eisenberg Dr. Daniele Piomelli Prof. Saoirse. O' Sullivan Dr. Joseph Tam Prof. Davis Mellar Prof. David Nutt SciSparc Scient
SciSparc Ltd./ADR — Investor Presentation (February 2021) on 6ix